The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).
 
Darren R. Feldman
Research Funding - Novartis; Seagen
 
James Hu
Honoraria - Eisai
Consulting or Advisory Role - Eisai
Speakers' Bureau - Eisai
Travel, Accommodations, Expenses - Eisai
 
Sandy Srinivas
Consulting or Advisory Role - Genentech/Roche
Speakers' Bureau - Genentech
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst)
 
Walter Michael Stadler
Honoraria - AstraZeneca; Bristol-Myers Squibb; CVS Caremark; Sotio
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; CVS Caremark; Sotio
Research Funding - Active Biotech (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Johnson & Johnson (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech
Other Relationship - American Cancer Society; UpToDate
 
Brian Addis Costello
Research Funding - GlaxoSmithKline/Novartis (Inst)
 
Leonard Joseph Appleman
Research Funding - Acerta Pharma (Inst); Agensys (Inst); Astellas Pharma (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Dendreon (Inst); Exelixis (Inst); Genentech/Roche (Inst); Medivation/Astellas; Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Sotio (Inst); Tokai Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bayer; Cerulean Pharma; Exelixis
 
Matthew I. Milowsky
Research Funding - Acerta Pharma (Inst); Agensys (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Sujata Patil
No Relationships to Disclose
 
Maria Bromberg
No Relationships to Disclose
 
Patrick Nolan
No Relationships to Disclose
 
Tanya B. Dorff
Honoraria - Astellas Pharma; Dendreon; Exelixis; Pfizer; Prometheus
Consulting or Advisory Role - Bayer; Dendreon; Eisai; EMD Serono; Janssen Oncology
Speakers' Bureau - Astellas Pharma; Dendreon; Exelixis; Pfizer; Prometheus
Research Funding - Bayer; Bristol-Myers Squibb
 
Victor E. Reuter
No Relationships to Disclose
 
Hikmat Al-Ahmadie
Consulting or Advisory Role - Bristol-Myers Squibb; EMD Serono
 
Samuel Funt
Stock and Other Ownership Interests - Hubble (I); Kite, a Gilead company; Second Science; Urogen pharma (I)
Research Funding - AstraZeneca; Genentech/Roche
 
Dean F. Bajorin
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EMD Serono; Fidia Farmaceutici S. p. A.; Genentech; Lilly; Lilly; Merck; Novartis; Pfizer; Roche; Roche/Genentech; Urogen pharma
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Roche/Genentech; Urogen pharma
 
George J. Bosl
No Relationships to Disclose
 
David I. Quinn
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; EMD Serono; Exelixis; Genentech/Roche; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; Peloton Therapeutics; Pfizer; Piramal Life Science; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; Eisai; EMD Serono; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Peloton Therapeutics; Pfizer; Piramal Life Science; Sanofi
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Sanofi (Inst)
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb